Earlier research demonstrated that immune checkpoint molecules (e.g., PD‐L1, LAG3) are involved in diverse biological processes and may serve as promising biomarkers for stratified prognosis or as excellent biomarkers for predicting the response to immune treatment in advanced urothelial carcinoma,30 colorectal cancer,31 and non‐small cell lung cancer.32 This evidence concerns the gene LAG3 and lung cancer.